Adoption, Acceptability, and Effectiveness of a Mobile Health App for Personalised Prostate Cancer Survivorship Care.
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT03207113|
Recruitment Status : Recruiting
First Posted : July 2, 2017
Last Update Posted : October 12, 2017
|Condition or disease||Intervention/treatment||Phase|
|Prostate Cancer||Behavioral: Ned||Not Applicable|
By 2030, prostate cancer will be the most commonly diagnosed cancer in North America. To mitigate this impending challenge, comprehensive support mechanisms for disease and treatment-specific changes in health and wellbeing must be proactively designed and thoughtfully implemented for streamlined survivorship care. Mobile health applications have been lauded as a promising complement to current outpatient treatment and monitoring strategies, but have not yet been widely used to support prostate cancer survivorship needs. A realist evaluation is needed to examine the impact of such applications on the prostate cancer survivorship experience.
The investigators seek to gain an understanding of how a mobile health application for prostate cancer survivorship care called Ned ("No Evident Disease") is adopted and accepted by patients, caregivers and clinicians. The investigators also aim to determine the effect of Ned on health-related quality of life, satisfaction with cancer care, unmet needs, self-efficacy, and prostate cancer-related levels of anxiety.
The Ned case study is a 12-month mixed methods embedded single-case study with a nested within-group pre-post comparison of health outcomes. 400 patients, 200 caregivers, and 10 clinicians will be given access to Ned. Participants will be asked to complete study assessments at baseline, 2 months, 6 months and 12 months. 30 semi-structured qualitative interviews will be conducted with patients (n=20) and their caregivers (n=10) post-study to gain insight into their experience with the application.
This will be the first realist case study to evaluate an application for prostate cancer survivorship care. Prostate cancer survivors are set to increase in number and longevity, heightening the need for integrated survivorship solutions to provide them with optimal and durable outcomes. The knowledge gained from this study will comprehensively inform how and why Ned works, for whom, and in what circumstances. Understanding the impact of digital health interventions like Ned on how survivors care for themselves is critical to realising patient-centered care.
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||610 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Primary Purpose:||Supportive Care|
|Official Title:||Adoption, Acceptability, and Effectiveness of a Mobile Health App for Personalised Prostate Cancer Survivorship Care: a Realist Case Study of the Ned App.|
|Estimated Study Start Date :||October 2017|
|Estimated Primary Completion Date :||March 2018|
|Estimated Study Completion Date :||March 2019|
Experimental: Ned Group
Participants in the Ned case study (patients, caregivers, clinicians) will receive access to the Ned application.
Ned ("No Evident Disease") is the first application to provide patients with access to individual-level prostate-specific antigen values streamed directly from the Ontario Laboratory Information System to their own smartphone. The application aims to promote self-care by informing patients directly of their PSA results and providing them with a personalised view of their own symptoms. It supports real-time clinical decision-making by providing clinicians with patient-reported outcomes collected in-app, and includes a curated educational feed and support group links.
Prostate cancer survivorship application.
- Adoption [ Time Frame: Continuous throughout 12 month study duration ]The number of patients, caregivers and clinicians who are invited to open a Ned account, and the consequent number of Ned accounts created; measured using analytics log data.
- Acceptability [ Time Frame: Continuous throughout 12 month study duration ]The perception of Ned as an acceptable addition to the standard of care; measured using (i) analytics log data (ii) validated questionnaires (iii) semi-structured interviews.
- Health-related quality of life [ Time Frame: 12 month study duration ]Health-related quality of life will be measured using a validated questionnaire. Data will be collected at baseline, 2 months, 6 months, and 12 months.
- Satisfaction with cancer care [ Time Frame: 12 month study duration ]Satisfaction with cancer care will be measured using a validated questionnaire. Data will be collected at baseline, 2 months, 6 months, and 12 months.
- Unmet needs [ Time Frame: 12 month study duration ]Unmet needs will be measured using a validated questionnaire. Data will be collected at baseline, 2 months, 6 months, and 12 months.
- Self-efficacy [ Time Frame: 12 month study duration ]Self-efficacy will be measured using a validated questionnaire. Data will be collected at baseline, 2 months, 6 months, and 12 months.
- Prostate cancer-related levels of anxiety [ Time Frame: 12 month study duration ]Prostate cancer-related levels of anxiety will be measured using a validated questionnaire. Data will be collected at baseline, 2 months, 6 months, and 12 months.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03207113
|Contact: Quynh Pham, MScfirstname.lastname@example.org|
|Centre for Global eHealth Innovation||Recruiting|
|Toronto, Ontario, Canada, M5G 2C4|
|Contact: Quynh Pham, MSc 1-647-667-2573 email@example.com|
|Principal Investigator: Andrew Feifer, MD, MPH|
|Sub-Investigator: Joseph A. Cafazzo, PhD, PEng|
|Sub-Investigator: Quynh Pham, MSc|
|Principal Investigator:||Andrew Feifer, MD, MPH||Trillium Health Partners|